NIBR189

Catalog No.S0183 Batch:S018302

Print

Technical Data

Formula

C21H21BrN2O3
Molecular Weight 429.31 CAS No. 1599432-08-2
Solubility (25°C)* In vitro DMSO 21 mg/mL (48.91 mM)
Ethanol 3 mg/mL (6.98 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.05mg/ml Taking the 1 mL working solution as an example, add 50 μL of clarified DMSO stock solution of 21 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description NIBR189 is a potent antagonist of the Epstein-Barr virus-induced gene 2 (EBI2, GPR183) receptor with IC50 of 16 nM for binding and 11 nM for function, respectively.
Targets
EBI2 (function) [1]
(Cell-free assay)		 EBI2 (binding) [1]
(Cell-free assay)
11 nM 16 nM
In vitro

NIBR189, the EBI2 antagonist, blocks the migration of U937 cells expressing functional EBI2 levels with an IC50 of 0.3 nM.[1]
In vivo

NIBR189 is a potent and selective EBI2 antagonist with pharmacokinetic properties which should allow use for in vitro and in vivo experiments.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    U937 cells

  • Concentrations

    20 nM

  • Incubation Time

    3 h

  • Method

    Prior to the migration assay, U937 cells were kept overnight in lipid-depleted media. Chemotaxis was performed using HTS Transwell-96 plates with 5.0 μm pore polycarbonate membranes. In brief, lower chambers were filled with 240 μL of compound solution in media in which the FCS was substituted with 1% BSA, and after insertion of the filters, 0.75×105 cells in 75 μL media were added to the upper chamber. After 3 h at 37℃, cells in the lower chamber were analyzed by flow cytometry.
Animal Study:

[1]
  • Animal Models

    C57BL/6 male mice

  • Dosages

    1 mg/kg (i.v.); 3 mg/kg (p.o.)

  • Administration

    i.v., p.o.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.